HC Wainwright Issues Negative Forecast for RYTM Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Equities research analysts at HC Wainwright cut their Q3 2027 EPS estimates for shares of Rhythm Pharmaceuticals in a report released on Monday, May 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.31 per share for the quarter, down from their previous estimate of $0.33. HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($3.04) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q4 2027 earnings at $0.66 EPS and FY2027 earnings at $0.53 EPS.

A number of other equities analysts have also recently weighed in on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Tuesday, March 3rd. Citigroup decreased their price target on Rhythm Pharmaceuticals from $136.00 to $131.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. Citizens Jmp lowered their price target on Rhythm Pharmaceuticals from $176.00 to $152.00 and set a “market outperform” rating for the company in a research report on Tuesday, March 17th. Zacks Research raised Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. Finally, Royal Bank Of Canada boosted their price objective on Rhythm Pharmaceuticals from $136.00 to $137.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $131.81.

Rhythm Pharmaceuticals Price Performance

NASDAQ RYTM opened at $87.39 on Tuesday. The stock has a market capitalization of $5.99 billion, a P/E ratio of -27.92 and a beta of 1.94. The firm’s 50-day moving average is $87.61 and its two-hundred day moving average is $98.97. Rhythm Pharmaceuticals has a 12 month low of $55.31 and a 12 month high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its earnings results on Tuesday, May 5th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.03. The company had revenue of $60.11 million for the quarter, compared to the consensus estimate of $55.78 million. Rhythm Pharmaceuticals had a negative return on equity of 203.25% and a negative net margin of 93.33%.The company’s revenue for the quarter was up 83.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.81) earnings per share.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other news, CAO Christopher Paul German sold 5,614 shares of Rhythm Pharmaceuticals stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $89.56, for a total value of $502,789.84. Following the completion of the transaction, the chief accounting officer owned 160 shares in the company, valued at approximately $14,329.60. This trade represents a 97.23% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Hunter C. Smith sold 4,385 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total transaction of $444,025.10. Following the completion of the transaction, the chief financial officer owned 110,512 shares of the company’s stock, valued at $11,190,445.12. This represents a 3.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 17,926 shares of company stock worth $1,737,778. Insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Several large investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC raised its stake in Rhythm Pharmaceuticals by 303.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $28,000 after buying an additional 200 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Rhythm Pharmaceuticals by 97.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock worth $29,000 after acquiring an additional 141 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Rhythm Pharmaceuticals by 1,110.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock worth $35,000 after acquiring an additional 322 shares in the last quarter. Optiver Holding B.V. increased its holdings in shares of Rhythm Pharmaceuticals by 65.2% in the 3rd quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock valued at $37,000 after acquiring an additional 144 shares during the last quarter. Finally, SBI Securities Co. Ltd. increased its holdings in shares of Rhythm Pharmaceuticals by 73.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock valued at $37,000 after acquiring an additional 145 shares during the last quarter.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical?stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin?4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.